MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Stent Thrombosis in BMS and DES
More issues than answers.
By Mitchell W. Krucoff, MD, FACC
Are New DES Designs Safer?
Changes in stent platform, polymer, and drug components have led to improved outcomes.
By Ashwani Sastry, MD, and Mitchell W. Krucoff, MD, FACC, FSCAI, FAHA
LEADERS FREE II Pivotal Trial Data Presented for Biosensors' Drug-Coated Stent
September 22, 2018—Biosensors International Group, Ltd. and BlueSail Medical announced that primary endpoint results of the LEADERS FREE II trial were presented by Mitchell W. Krucoff, MD, at TCT 2018, the 30th annual Transcatheter Cardiovascular Therapeutics scientific symposium held September 21–25 in San Diego, California.
2008 Drug-Eluting Stent Update
By Ted E. Feldman, MD, FSCAI, Chief Medical Editor
Chief Medical Editor's Page: DES Evolution
By Ted E. Feldman, MD, FSCAI
Biosensors BioFreedom DCS Devices Approved in United States and Japan
May 3, 2022—Biosensors International Group, Ltd. announced FDA approval for the polymer-free and carrier-free BioFreedom drug-coated stent (DCS) in the United States and approval by the Pharmaceuticals and Medical Devices Agency in Japan of the BioFreedom Ultra DCS for percutaneous coronary intervention (PCI).
Highlights from EuroPCR
DES, COURAGE, and the Great Debate
Does the Metal Matter?
An overview of next-generation stent platforms.
By Louis A. Cannon, MD, Fscai, FACC, FACP; Gary A. Daniel, MD; Kristin L. Hood, PHD; and Steven J. Yakubov, MD, FACC
